On 20th October 2015, Trajan hosted a BioMelbourne Network Bio-Briefing event at their corporate headquarters in Ringwood, Melbourne, Victoria – “Quality initiatives: Transformation and Training for Building Business Value”.
Approximately 25 BioMelbourne members attended to gain insights on industry quality incentives and issues, with presentations delivered by:
• Mr David Spaulding, Senior Consultant and Training Manager, SeerPharma
Mr Spaulding presented an overview of methods to reducing errors through best practise training and highlighted how the inability to incorporate systematic processes can have a draining effect on the value of businesses.
• Mr Steven van Winckel, General Manager, Glass Technologies, Trajan Scientific and Medical
Mr van Winckel’s presentation concentrated on quality initiatives for manufacturing transformation, and outlined the importance of data collection to analyze production issues leading to the implementation of better work practices to reduce waste, decrease productivity costs and increase department efficiencies.
Attendees also had the opportunity to experience a short tour of Trajan's Ringwood manufacturing facility and witness first-hand how some of the incentives discussed have been implemented within the Glass Technologies business unit.
This event was another mechanism showcasing Trajan’s desire to collaborate with industry partners to promote life science activities and stimulate local interaction to enhance industry success.
Photo: BioMelbourne Network Chief Executive Officer Dr Krystal Evans welcomes guests to Trajan Scientific and Medical
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.